St George Cancer Care Centre, Kogarah, New South Wales, Australia.
St George Cancer Care Centre, Kogarah, New South Wales, Australia; Centre for Medical Radiation Physics, University of Wollongong, Wollongong, New South Wales, Australia.
Brachytherapy. 2021 May-Jun;20(3):655-663. doi: 10.1016/j.brachy.2020.11.013. Epub 2021 Jan 7.
The aim of the study was to conduct a retrospective analysis of 100 patients who received interstitial accelerated partial breast irradiation at a single institution, comparing the standard American Association of Physicists in Medicine Task Group (TG) 43 dose calculation algorithm to the model-based dose calculation algorithms (MBDCAs) available in the Oncentra Brachy treatment planning system.
Dose-volume histogram parameters were compared between the different dose calculation algorithms for the planning target volume and organs at risk. and a statistical analysis was performed. The resulting changes in isodose distribution were assessed, with the worst-case data presented.
The TG43 algorithm calculated higher doses to all structures compared with the MBDCAs. The largest discrepancy was observed for the skin, with maximum doses on average 2.0% lower with the MBDCA. The newly released Hounsfield Unit-based algorithm further decreased the skin dose compared with TG43 by <0.5%.
This study demonstrates that the differences between TG43 and MBDCA as implemented in Oncentra Brachy for accelerated partial breast irradiation are clinically insignificant in the treatment area and nearby organs at risk. Justification for investing in MBDCAs for this treatment site is limited when considering the additional calculation time, introduced uncertainties, and cost.
本研究旨在对在一家机构接受间质加速部分乳房照射的 100 例患者进行回顾性分析,比较标准的美国医学物理学家协会任务组(TG)43 剂量计算算法与 Oncentra 近距离治疗计划系统中可用的基于模型的剂量计算算法(MBDCAs)。
比较了不同剂量计算算法在计划靶区和危及器官的剂量-体积直方图参数,并进行了统计学分析。评估了等剂量分布的变化,给出了最坏情况下的数据。
TG43 算法计算的所有结构的剂量均高于 MBDCAs。皮肤的差异最大,MBDCA 平均使最大剂量低 2.0%。新发布的基于亨氏单位的算法与 TG43 相比,使皮肤剂量进一步降低了<0.5%。
本研究表明,在 Oncentra 近距离治疗加速部分乳房照射中,TG43 和 MBDCA 之间的差异在治疗区域和附近的危及器官中临床意义不大。考虑到额外的计算时间、引入的不确定性和成本,对 MBDCAs 进行投资的理由有限。